Abstract
The aim. Combination therapy is used to treat hypertension. Strengthening the action of the ACE inhibitor enalapril is carried out in combination with the thiazide diuretic hydrochlorothiazide. On the pharmaceutical market, such combined preparations are presented by different manufacturers in various concentrations of the active ingredients of enalapril maleate and hydrochlorothiazide. Development of methods for the quantitative determination of active substances in combined drugs by liquid chromatography is topical.
 Materials and methods. Shimadzu Nexera X2 LC-30AD liquid chromatograph equipped with DAD SPD-M20A diode array detector, SIL-30AC autosampler and CTO-20AC column thermostat; analytical balance - UniBloc AUW120D; pH meter - Knick type 911pH; chromatographic column ACE C18, size 250 mm × 4.6 mm, packed with octadecylsilyl silica gel for chromatography with a particle size of 5 μm.
 Results. Based on the results of the work, a method for the quantitative determination of enalapril and hydrochlorothiazide in the presence of HPLC was proposed. The obtained validation characteristics indicate that the method for the quantitative determination of hydrochlorothiazide in Enalapril-H tablets corresponds to the following parameters: correctness, precision, linearity ( =0.70 ≤ max =1.60, d=0.22 ≤ maxd = 0.51, a=0.71 max a=2.60, r = 0.9997 min r=0.9981). In the quantitative determination of enalapril maleate in combined tablets, it was found that correctness, precision, linearity are performed ( =1.21 ≤ max =1.60, d=0.24 ≤ max d=0.51, a=1.35 max a=2.60, r = 0.9991 min r= 0.9981).
 Conclusions. The method of quantitative chromatographic determination of enalapril maleate and hydrochlorothiazide in an antihypertensive combination drug has been improved. The proposed parameters of the chromatographic separation of the mixture in comparison with the initial ones contribute to a decrease in the costs of monitoring, a decrease in the volume of harmful emissions and cause an extension of the life of the chromatographic column
Highlights
Treatment of hypertension to date, according to protocols approved by the Ministry of Health of Ukraine, is the first line drugs, which include thiazide diuretics; calcium channel antagonists (CCB); angiotensin-converting enzyme inhibitors (ACEI); angiotensin receptor antagonists and β-adrenoceptor blockers [1]
To test the proposed methods for determining the active substances of hydrochlorothiazide and enalapril maleate in the combined drug used commercial batches of the drug presented on the pharmaceutical market of Ukraine, which were purchased at the pharmacy
The determination is performed by liquid chromatography (SPhU / EP, 2.2.29, current edition)
Summary
Treatment of hypertension to date, according to protocols approved by the Ministry of Health of Ukraine, is the first line drugs, which include thiazide (thiazidelike) diuretics; calcium channel antagonists (CCB); angiotensin-converting enzyme inhibitors (ACEI); angiotensin receptor antagonists and β-adrenoceptor blockers [1]. One of the most common combinations of antihypertensive drugs is a combination of ACEI and thiazide diuretics (most often enalapril and hydrochlorothiazide) [4, 5]. Such therapy is well tolerated by patients, allows to influence systolic and diastolic pressure. The combination of enalapril with hydrochlorothiazide enhances the hypotensive effect due to the synergism of the two drugs: the diuretic lowers blood pressure, while increasing the level of renin, which, in turn, is acted by ACEI, which has an antihypertensive effect by the above mechanisms [7, 8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
